Artoss
Driving the Future of Bone Grafting

The joy of riding a bicycle is one experienced by many people around the world while growing up. The learning process, however, comes with a few cuts and bruises, and in worse cases, a fractured limb. While a bicycle fall may warrant a simple cast and some bed rest; a fall off a speeding motorcycle, on the other hand, may result in a more severe situation where the patient might require extensive orthopedic treatments to recover completely. Among the numerous treatments a patient might have to undergo, bone grafting is likely to be the most expensive and requires intensive rehabilitation. “If there is a challenge we’re addressing, it is the delivery of a product that provides an excellent clinical outcome at a very good price,” says Paul Byerley, managing director of Artoss, distributor of NanoBone^® Bone Graft in the U.S.

NanoBone is an advanced bone-grafting product leveraging nanobiology developed at the University of Rostock, Germany. Unlike other grafting products that require processes such as defrosting frozen grafts or mixing harvested bone tissues, NanoBone—a synthetic bone grafting material—was conceived to be a standalone product that enabled surgeons to operate expeditiously. “NanoBone can simply be taken off the shelf at room temperature, opened, and delivered to a surgeon in a ready-to-use applicator,” states James Cassidy, managing director of Artoss. This feature of NanoBone aids in removing several time-consuming steps for the OR staff and surgeons, while providing a better experience for both the surgeon and the patient.

As an effective, standalone bone grafting material, NanoBone is able to harness and stimulate a patient’s metabolism for bone healing and remodeling. “It is, in many respects, a product of regenerative medicine,” explains Cassidy. After implantation, NanoBone morphs into an organic matrix designed to support bone formation and the silica component stimulates angiogenesis, the formation of new blood vessels at the affected location, bringing cells and growth factors to the site.

As an effective, standalone bone grafting material, NanoBone is able to harness and stimulate a patient’s metabolism for bone healing and remodeling

NanoBone offers lower risks and is more economical than allografts and other orthopedic products requiring the addition of blood or bone marrow aspirate. These aspects prompted a prominent orthopedic surgeon in Phoenix, Arizona, to implement NanoBone in one of his cases. The surgeon encountered a patient with an open fracture of the leg. Six weeks after administering antiseptic treatments, the surgeon used 10cc of NanoBone to graft the bone back into its respective shape and form. After a period of three months, the product had mended the fracture, and the patient was declared clinically—and radiographically—healed.

With over 100,000 patients benefitting from the effectiveness of NanoBone, Artoss has become a prominent name in the healthcare industry as a cutting-edge applied nanobiology firm. Moving forward, the company expects to expand its team in the U.S. and is optimistic about its overall growth as an enterprise. Awaiting FDA approval for two new products, Byerley and Cassidy are confident in the prospects 2019 holds for the nanobiology firm. Artoss intends to continually deliver products that aid both the healthcare providers and consumers across all health departments in the industry.